Folio News Story
February 17, 2006

New centre to help understand and treat organ transplant rejection

Research could lead to earlier identification of organ transplantation, better anti-rejection drugs for patients

by Caitlin Crawshaw
Folio Staff
Dr. Phil Halloran holds a gene chip, a handheld device that records genes in tissue samples, and can predict organ rejection in transplant patients. The first project of The Alberta Transplant Institute Applied Genomics Centre will involve further development of the chip.
Dr. Phil Halloran holds a gene chip, a handheld device
that records genes in tissue samples, and can predict
organ rejection in transplant patients. The first project
of The Alberta Transplant Institute Applied Genomics
Centre will involve further development of the chip.

A new genomics centre at the University of Alberta is exploring ways to help transplant patients fight organ rejection.

The Alberta Transplant Institute Applied Genomics Centre has been kick-started by a $1-million gift from the Alberta government. Additionally, Roche Molecular Diagnostics will provide the gene expression analysis technology and Roche Pharmaceuticals will contribute an unrestricted grant towards the project. Both the University of Alberta and Capital health will contribute funds, work space and resources.

Initially, the centre will study kidney transplant patients to develop a better understanding of transplant disease mechanisms and rejection, said Dr. Phil Halloran, head of the Genome Canada Transplant Transcriptome Project at the U of A. He explained that the centre's first project will explore the application of gene chip technology, which records genes in a hand-held device. The technology has great potential for treating transplant patients, as it can predict organ rejection before it occurs, allowing doctors to adjust doses of anti-rejection medications, and preventing subsequent tissue damage.

"The project is designed to take the new gene technology and look at it in experimental animals and in humans, starting with kidneys and then going to other organs," said Halloran, who has been developing the use of gene-chip technology in organ transplants for two years. His lab was initially funded by the Faculty of Medicine and Dentistry, and Genome Canada, the latter contributing $18 million to U of A genomics research in 2004.

"The long-term consequences will be greater understanding and new diagnostic tools that we can use in the patients. So we're already getting new insights into the ways diseases behave in the patients, and we're already seeing limitations in the way we were doing things before."

The current method of identifying organ rejection - the consequence of the body's immune responses to foreign matter - is a 150-year-old technique of examining tissue with a microscope, called histology. The gene chip or micro-array could make diagnosis far more accurate and efficient.

The research centre will also help in the understanding of the mechanisms of disease itself, so better diagnoses can be made, and better anti-rejection drugs developed.

"The existing information (about transplant rejection) is inadequate, our existing diagnostic systems are inadequate and it's costing people opportunities for a long life," he added.

According to Alberta Innovation and Science Minister Victor Doerksen, the centre is valuable in terms of how it will help patients, and is commercially appealing.

"We are proud to be a part of this initiative, which could improve the quality of life for transplant patients, and make Alberta a leader in diagnostic technologies for organ transplantation. This investment in technology commercialization will ensure that the benefits of investments in research, technology and innovation - such as jobs, businesses and economic growth - stay in Alberta."